DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes

Information source: Zekai Tahir Burak Women's Health Research and Education Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infertility

Intervention: Leuprolide acetate (Drug); vaginal progesterone (Drug); 4 mg oral estradiol valerate (Drug)

Phase: N/A

Status: Not yet recruiting

Sponsored by: Zekai Tahir Burak Women's Health Research and Education Hospital

Official(s) and/or principal investigator(s):
Nagihan Cengaver, Resident, Principal Investigator, Affiliation: Zekai Tahir Burak Women's Health Research and Education Hospital

Overall contact:
Nagihan Cengaver, MD, Phone: +905556309298, Email: nagihancengaver@gmail.com

Summary

This prospective clinical trial evaluates the effect of a two dose GnRH agonist administered in the luteal phase on the outcome of ART cycles stimulated with the long GnRH agonist and GnRH antagonist protocol.

Clinical Details

Official title: To Evaluate the Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes in Both GnRH Agonist and GnRH Antagonist Treated Ovarian Stimulation Protocols

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Live Birth Rate

Secondary outcome:

Ongoing pregnancy

miscarriage

OHSS

Detailed description: This prospective clinical trial evaluates the effect of a two dose GnRH agonist administered in the luteal phase on the outcome of ART cycles stimulated with the long GnRH agonist and GnRH antagonist protocol. Decision between each of these two protocols was subjective and depended on the clinical context. In addition to routine luteal phase support with progesterone and estradiol valerate,women received two dose of GnRH agonist on the fifth and tenth day after ET. Live birth rate was the primary outcome measure.

Eligibility

Minimum age: 18 Years. Maximum age: 38 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Couples undergoing ART with their own gametes.

- Couples having at least one good embryo available for transfer.

- Normoresponder

- Infertility etiology is unexplained

- ovulation triggered by intramuscular injection of 10000 IU of HCG

Exclusion Criteria: Patients older than 38 years old

- High and poor responder patients

Locations and Contacts

Nagihan Cengaver, MD, Phone: +905556309298, Email: nagihancengaver@gmail.com

Zekai Tahir Burak Hospital, Ankara, Cankaya 06500, Turkey
Additional Information

Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.

Starting date: April 2014
Last updated: April 13, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017